FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564173629> ?p ?o ?g. }

• W2564173629 endingPage "69" @default.
• W2564173629 startingPage "61" @default.
• W2564173629 abstract "PurposeTo assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids.DesignRandomized, controlled, observer-masked clinical trial.Methodssetting: Two US clinical sites. patient population: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months. intervention: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids. main outcome measure: Adherence with administered medication, as recorded by the dosing aids.ResultsMean ± SD patient age was 60 ± 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on ≥80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group).ConclusionsPatients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy. To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids. Randomized, controlled, observer-masked clinical trial. setting: Two US clinical sites. patient population: Eligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension. Patients (n = 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12 months. intervention: TTFC was administered once daily in the morning or evening with a single dosing aid. Patients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids. main outcome measure: Adherence with administered medication, as recorded by the dosing aids. Mean ± SD patient age was 60 ± 10 years; most patients were male and white. Compared with TRAV+TIM (n = 40), patients receiving TTFC (n = 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%). At months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively. Significantly more patients were adherent on ≥80% of days with TTFC compared with TRAV+TIM (P < .001 to P = .041). Both treatments reduced IOP from baseline, and no safety issues were identified in either group. Ocular hyperemia was the most common treatment-related adverse event (n = 3/group). Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRAV+TIM through 12 months of on-therapy evaluation. This suggests that, for patients requiring multiple IOP-lowering medications, a fixed combination may provide improved long-term adherence compared with unfixed therapy." @default.
• W2564173629 created "2017-01-06" @default.
• W2564173629 creator A5044721818 @default.
• W2564173629 creator A5045266317 @default.
• W2564173629 date "2017-04-01" @default.
• W2564173629 modified "2023-09-27" @default.
• W2564173629 title "Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: A Randomized Trial" @default.
• W2564173629 cites W1976180471 @default.
• W2564173629 cites W1976253654 @default.
• W2564173629 cites W1978868967 @default.
• W2564173629 cites W1979727810 @default.
• W2564173629 cites W1981201333 @default.
• W2564173629 cites W2011292331 @default.
• W2564173629 cites W2019255097 @default.
• W2564173629 cites W2020555111 @default.
• W2564173629 cites W2023077048 @default.
• W2564173629 cites W2038661707 @default.
• W2564173629 cites W2040211497 @default.
• W2564173629 cites W2041031004 @default.
• W2564173629 cites W2056317022 @default.
• W2564173629 cites W2059051877 @default.
• W2564173629 cites W2066361855 @default.
• W2564173629 cites W2070099990 @default.
• W2564173629 cites W2074079712 @default.
• W2564173629 cites W2078889609 @default.
• W2564173629 cites W2085211662 @default.
• W2564173629 cites W2088139852 @default.
• W2564173629 cites W2091441457 @default.
• W2564173629 cites W2091957048 @default.
• W2564173629 cites W2107869569 @default.
• W2564173629 cites W2117850639 @default.
• W2564173629 cites W2122691108 @default.
• W2564173629 cites W2140594570 @default.
• W2564173629 cites W2148890166 @default.
• W2564173629 cites W2158120673 @default.
• W2564173629 cites W2163815596 @default.
• W2564173629 cites W2249691923 @default.
• W2564173629 cites W2323837062 @default.
• W2564173629 cites W1998050535 @default.
• W2564173629 doi "https://doi.org/10.1016/j.ajo.2016.12.002" @default.
• W2564173629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27993589" @default.
• W2564173629 hasPublicationYear "2017" @default.
• W2564173629 type Work @default.
• W2564173629 sameAs 2564173629 @default.
• W2564173629 citedByCount "38" @default.
• W2564173629 countsByYear W25641736292017 @default.
• W2564173629 countsByYear W25641736292018 @default.
• W2564173629 countsByYear W25641736292019 @default.
• W2564173629 countsByYear W25641736292020 @default.
• W2564173629 countsByYear W25641736292021 @default.
• W2564173629 countsByYear W25641736292022 @default.
• W2564173629 countsByYear W25641736292023 @default.
• W2564173629 crossrefType "journal-article" @default.
• W2564173629 hasAuthorship W2564173629A5044721818 @default.
• W2564173629 hasAuthorship W2564173629A5045266317 @default.
• W2564173629 hasBestOaLocation W25641736291 @default.
• W2564173629 hasConcept C118487528 @default.
• W2564173629 hasConcept C121332964 @default.
• W2564173629 hasConcept C126322002 @default.
• W2564173629 hasConcept C1276947 @default.
• W2564173629 hasConcept C168563851 @default.
• W2564173629 hasConcept C19720800 @default.
• W2564173629 hasConcept C197934379 @default.
• W2564173629 hasConcept C2776476923 @default.
• W2564173629 hasConcept C2776521421 @default.
• W2564173629 hasConcept C2777288759 @default.
• W2564173629 hasConcept C2778073030 @default.
• W2564173629 hasConcept C2778527774 @default.
• W2564173629 hasConcept C2780276452 @default.
• W2564173629 hasConcept C2781092963 @default.
• W2564173629 hasConcept C71924100 @default.
• W2564173629 hasConceptScore W2564173629C118487528 @default.
• W2564173629 hasConceptScore W2564173629C121332964 @default.
• W2564173629 hasConceptScore W2564173629C126322002 @default.
• W2564173629 hasConceptScore W2564173629C1276947 @default.
• W2564173629 hasConceptScore W2564173629C168563851 @default.
• W2564173629 hasConceptScore W2564173629C19720800 @default.
• W2564173629 hasConceptScore W2564173629C197934379 @default.
• W2564173629 hasConceptScore W2564173629C2776476923 @default.
• W2564173629 hasConceptScore W2564173629C2776521421 @default.
• W2564173629 hasConceptScore W2564173629C2777288759 @default.
• W2564173629 hasConceptScore W2564173629C2778073030 @default.
• W2564173629 hasConceptScore W2564173629C2778527774 @default.
• W2564173629 hasConceptScore W2564173629C2780276452 @default.
• W2564173629 hasConceptScore W2564173629C2781092963 @default.
• W2564173629 hasConceptScore W2564173629C71924100 @default.
• W2564173629 hasLocation W25641736291 @default.
• W2564173629 hasLocation W25641736292 @default.
• W2564173629 hasOpenAccess W2564173629 @default.
• W2564173629 hasPrimaryLocation W25641736291 @default.
• W2564173629 hasRelatedWork W1977459700 @default.
• W2564173629 hasRelatedWork W1999304281 @default.
• W2564173629 hasRelatedWork W2046688990 @default.
• W2564173629 hasRelatedWork W2048014260 @default.
• W2564173629 hasRelatedWork W2092664751 @default.
• W2564173629 hasRelatedWork W2114044392 @default.
• W2564173629 hasRelatedWork W2127788241 @default.
• W2564173629 hasRelatedWork W2128476364 @default.

• next